SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025. It plans to buy back shares worth 5 billion euro in 2025.

More than 85% of Altuviiio’s sales were in the United States. New drug, Nexviazyme/Nexviadzyme recorded sales of €184 million, up 42.0% year over year. While sales were strong in Europe and ...

A high dividend yield of over 4%, revenue growth of over 15% due to strong sales of Nexviazyme/Nexviadyme, Rezurock, Xenpozyme, Dupixent and Toujeo are the factors due to which I am increasing the ...

The drug was registered in the US last year as Nexviazyme. It is an updated version of Sanofi's blockbuster Myozyme/Lumizyme (alglucosidase alfa) therapies for Pompe, but is designed to be more ...

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut ...